Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Rhea-AI Summary

Jupiter Neurosciences (NASDAQ:JUNS) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026 at The Borgata Hotel, Casino & Spa in Atlantic City, NJ.

Christer Rosén, Chairman and CEO, will deliver a company presentation and is available for one-on-one investor meetings. Investors can request an investor pass at no cost to attend. More information about the company is available at the company website.

Market Reality Check

Price: $0.8250 Vol: Volume 29,089 is at 0.35x...

low vol

$0.8250 Last Close

Volume Volume 29,089 is at 0.35x the 20-day average of 83,984, suggesting limited pre-news trading interest. low

Technical Shares at $0.825 trade below the $1.21 200-day MA, standing 75.23% under the 52-week high and 61.76% above the 52-week low.

Peers on Argus

Pre-news, JUNS was down 7.3% with mixed peer action: several biotech peers such ...

3 Up 1 Down

Pre-news, JUNS was down 7.3% with mixed peer action: several biotech peers such as MAIA and APLT were up, while SER was down, pointing to stock-specific factors rather than a unified sector move.

Historical Context

5 past events · Latest: Dec 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 23	Investor webinar invite	Positive	-2.7%	Announcement of an investor webinar reviewing JOTROL and pipeline plans.
Dec 03	Year-in-review update	Positive	+2.5%	Update on first public year, JOTROL progress, Nugevia launch, and financing.
Dec 02	Conference participation	Positive	-1.7%	Participation and 1x1 meetings at NobleCon21 emerging growth conference.
Nov 05	IND clearance	Positive	+8.8%	FDA clearance of IND to start Phase 2a Parkinson’s trial for JOTROL.
Oct 27	Financing agreement	Positive	+11.1%	Yorkville financing agreements providing up to $20M to fund trials and Nugevia.

Pattern Detected

Investor-relations and conference/webinar announcements have previously seen mixed-to-negative reactions, while substantive clinical and financing milestones have tended to coincide with positive moves.

Recent Company History

Over the last few months, JUNS reported several milestones, including FDA clearance of an IND for a Phase 2a Parkinson’s trial on Nov 5, 2025 and flexible financing arrangements for up to $20 million. Investor-outreach items such as conferences and webinars on Dec 2 and Dec 23, 2025 coincided with modest share declines, while the IND clearance and Yorkville financing on Oct 27, 2025 were followed by stronger positive price reactions. Today’s conference participation fits the pattern of non-fundamental outreach news.

Market Pulse Summary

This announcement highlights JUNS’s continued investor-relations outreach, with management presentin...

Analysis

This announcement highlights JUNS’s continued investor-relations outreach, with management presenting and holding one-on-one meetings at the DealFlow Discovery Conference on January 28–29, 2026. Recent history shows that conference and webinar news tended to have smaller or negative price reactions, while substantive milestones like FDA IND clearance and financing access up to $20 million were associated with stronger moves. Monitoring future clinical trial progress and funding updates remains important alongside these visibility-building events.

Key Terms

clinical-stage, resveratrol-based, neuroinflammation, one-on-one investor meetings

4 terms

clinical-stage medical

"Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

resveratrol-based medical

"developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging"

Products, treatments, or formulations that use resveratrol—a naturally occurring compound found in certain plants—as a primary active ingredient or key selling feature. For investors, “resveratrol-based” signals a focus on antioxidant, anti-inflammatory, or longevity claims that can affect market demand, regulatory review, and clinical evidence requirements; think of it as a product built around a single headline ingredient, like a car marketed mainly for its electric motor. The term does not guarantee effectiveness or regulatory approval.

neuroinflammation medical

"a patented resveratrol-based platform for neuroinflammation and healthy aging"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

one-on-one investor meetings financial

"will deliver a company presentation and be available for one-on-one investor meetings"

One-on-one investor meetings are private conversations between company representatives and individual investors, where they discuss the company's performance, plans, and outlook. These meetings help investors gain a clearer understanding of the company’s future prospects, much like a personal consultation, enabling them to make more informed decisions about their investments. They are an important way for investors to build trust and gather detailed insights directly from company leaders.

AI-generated analysis. Not financial advice.

JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Jupiter Neurosciences at www.jupiterneurosciences.com.

Event Details:

• Conference: 3rd Annual DealFlow Discovery Conference

• Venue: The Borgata Hotel, Casino & Spa

• Location: Atlantic City, NJ

• Date: January 28-29, 2026

Investors interested in scheduling a meeting with the Jupiter Neurosciences management team should request an investor pass to attend the conference (no cost to attend).

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Media Contact:

Christer Rosén
Chairman and CEO
Jupiter Neurosciences, Inc.
IR@jupiterneurosciences.com

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

FAQ

When and where will Jupiter Neurosciences (JUNS) present at the DealFlow Discovery Conference?

Jupiter Neurosciences will present on January 28-29, 2026 at The Borgata Hotel, Casino & Spa in Atlantic City, NJ.

Who from Jupiter Neurosciences will speak at the DealFlow Discovery Conference?

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver the company presentation and meet investors one-on-one.

How can investors schedule a meeting with Jupiter Neurosciences management at the JAN 2026 DealFlow conference?

Investors should request an investor pass to attend the conference and schedule one-on-one meetings with management; attendance is stated as no cost.

What topics will Jupiter Neurosciences likely cover in the DealFlow presentation?

The presentation will focus on the company's clinical-stage program for JOTROL™, its resveratrol-based platform for neuroinflammation and healthy aging.

Where can I find more information about Jupiter Neurosciences (JUNS) before the conference?

Company information is available on the corporate website at www.jupiterneurosciences.com.